Clinical Trial Update: First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer [Phase 1]

View source ↗

Summary

First-in-human Phase 1 study of RLY-2608, a mutant-selective PI3Kα inhibitor, in adults with advanced solid tumors. The trial also evaluates combinations with e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors

Drugs mentioned

• RLY-2608

Snippet

Sponsor: Relay Therapeutics, Inc. | Conditions: PIK3CA Mutation, Solid Tumor, Adult | Phase 1 | Status: RECRUITING